2-[(2R)-2-methylpiperazin-1-yl]-3-[2-[2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]pyridin-3-yl]oxyethoxy]pyrazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-[(2R)-2-methylpiperazin-1-yl]-3-[2-[2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]pyridin-3-yl]oxyethoxy]pyrazine
• 化学式: C₂₂H₃₂N₆O₃
• 分子量: 428.5
• InChiKey: AAMYDEYHEGHOKG-MSOLQXFVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  31
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  84.9
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• Novel compounds, their use and preparation
  申请人：——

  公开号：US20040029888A1

  公开（公告）日：2004-02-12

  The invention relates to compounds of the general Formula (I): 1 The compounds may be prepared by per se conventional methods and can be used for treating a human or animal subject suffering from a serotonin-related disorder. The invention also relates to such use as well as to pharmaceutical compositions comprising a compound of Formula (I).

  本发明涉及通式（I）的化合物：1这些化合物可以通过常规方法制备，可用于治疗患有血清素相关疾病的人类或动物受试者。本发明还涉及这种用途以及包含通式（I）化合物的制药组合物。
• Treatment of incontinence with 5htc2 agonists
  申请人：Pfizer Inc.

  公开号：EP2277513A2

  公开（公告）日：2011-01-26

  The present invention relates to the use of agonists of 5-HT2C receptors for the treatment of stress urinary incontinence. The present invention also relates to a method of treatment of stress urinary incontinence, to assays to screen for compounds useful in the treatment of stress urinary incontinence, and to methods of preparing compositions for the treatment of stress urinary incontinence.

  本发明涉及使用5-HT2C受体激动剂治疗压力性尿失禁。本发明还涉及一种治疗压力性尿失禁的方法，涉及筛选用于治疗压力性尿失禁的化合物的检测方法，以及涉及制备治疗压力性尿失禁的组合物的方法。
• NOVEL COMPOUNDS, THEIR USE AND PREPARATION
  申请人：Biovitrum AB

  公开号：EP1513831A1

  公开（公告）日：2005-03-16
• TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS
  申请人：Pfizer Limited

  公开号：EP1620081A2

  公开（公告）日：2006-02-01
• Treatment of Incontinence
  申请人：McMurray Gordon

  公开号：US20080146583A1

  公开（公告）日：2008-06-19

  The present invention relates to the use of agonists of 5-HT2C receptors for the treatment of urinary incontinence, preferably mixed incontinence or stress urinary incontinence. The invention also relates to the use of antagonists of 5-HT2C receptors for the treatment of urine retention. The present invention also relates to a method of treatment of incontinence, to assays to screen for compounds useful in the treatment of incontinence, and to methods of preparing compositions for the treatment of urinary incontinence.